TVTX:NASDAQTravere Therapeutics, Inc. Analysis
Data as of 2026-05-06 - not real-time
$44.76
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
FDA approval of FILSPARI for FSGS ignited an 88% YoY sales jump to $105 M and lifted TVTX’s share price to $44.76, comfortably above its 20‑day SMA of 39.87 and 50‑day SMA of 33.15, signalling a bullish trend. The MACD line sits above its signal (3.33 vs 3.08) while the RSI is at 72, indicating strong upward momentum but also an overbought condition; support sits at $28.29 with resistance near $48.61.
Valuation looks attractive with a forward P/E of 8.87 versus the industry average of 26.80, yet a lofty P/B of 35.44 and a debt‑to‑equity ratio exceeding 330% highlight balance‑sheet strain. Analysts collectively rate the stock as a strong buy with a median price target of $53.50, reflecting confidence in the growth trajectory despite cash‑flow and leverage concerns.
Valuation looks attractive with a forward P/E of 8.87 versus the industry average of 26.80, yet a lofty P/B of 35.44 and a debt‑to‑equity ratio exceeding 330% highlight balance‑sheet strain. Analysts collectively rate the stock as a strong buy with a median price target of $53.50, reflecting confidence in the growth trajectory despite cash‑flow and leverage concerns.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 8/10
Key Factors
- Recent FDA full approval expanding addressable market
- Technical bullish indicators (price above SMAs, MACD bullish)
- Analyst consensus strong‑buy and upside potential
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Sustained revenue growth and expanding sales of FILSPARI
- Forward P/E advantage relative to industry peers
- Need to manage high leverage and improve cash flow
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Long‑term market potential in rare kidney diseases
- Balance‑sheet risk from elevated debt‑to‑equity ratio
- Uncertainty around pipeline success beyond current products
Key Metrics & Analysis
Financial Health
Revenue Growth55.60%
Profit Margin-4.00%
P/E Ratio8.9
ROE-69.38%
ROA-6.46%
Debt/Equity331.88
P/B Ratio35.4
Industry P/E26.8
Technical Analysis
TrendBullish
RSI72.0
Support$28.29
Resistance$48.61
MA 20$39.87
MA 50$33.15
MA 200$29.20
MACDBullish
VolumeDecreasing
Fear & Greed Index90.38
Valuation
Target Price$52.50
Upside/Downside17.29%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta1.77
Volatility104.66%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.